Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

Hengrui Pharmaceuticals Advances in Breast Cancer Treatment with NMPA Clinical Trial Greenlight

Fineline Cube Jul 29, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a pharmaceutical heavyweight based in China, has received...

Company Medical Device

MicroPort MedTech’s Aortic Occlusion Catheter Gets Green Light from China’s NMPA

Fineline Cube Jul 29, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical technology...

Company Drug

Zhejiang Haichang Biotech Secures EU Approval for Apexelsin: A New Hope in Cancer Treatment

Fineline Cube Jul 29, 2024

Zhejiang Haichang Biotech Co., Ltd, a partner of China-based Kexing Pharmaceutical (SHA: 688136), has secured...

Policy / Regulatory

China Unveils Comprehensive 2030 Plan to Combat Diabetes

Fineline Cube Jul 29, 2024

China’s National Health Commission (NHC), in collaboration with 12 other ministries, has unveiled the ‘Health...

Company Deals R&D

CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab

Fineline Cube Jul 29, 2024

China National Biotec Group Company Ltd (CNBG) has announced a strategic collaboration with the University...

Company Deals

Tigermed Expands Asia Pacific Presence with Acquisition of Japanese CRO Medical Edge

Fineline Cube Jul 26, 2024

Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the...

Company Deals

Shanghai Escugen Partners with Innolake Biopharma to Develop Novel ADCs Using EZWi-Fit Platfo

Fineline Cube Jul 26, 2024

Shanghai Escugen, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese...

Company Drug

Belief BioMed’s Hemophilia B Gene Therapy BBM-H901 Slated for Priority Review in China

Fineline Cube Jul 26, 2024

The Center for Drug Evaluation (CDE) has indicated on its website that the market application...

Policy / Regulatory

NHSA Report: China’s Medical Insurance Fund Records Significant Growth and Savings in 2023

Fineline Cube Jul 26, 2024

The National Healthcare Security Administration (NHSA) has released its comprehensive annual statistical report for the...

Company Deals R&D

CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine

Fineline Cube Jul 26, 2024

CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic...

Company Deals

Shanghai’s Spectrum Dynamics Medical Secures Major Financing for Molecular Imaging Innovations

Fineline Cube Jul 26, 2024

Spectrum Dynamics Medical, a Shanghai-based specialist in medical molecular imaging, has reportedly secured hundreds of...

Company Deals

Shanghai GenTech Expands into Life Sciences with Acquisition of Konosai Biotechnology

Fineline Cube Jul 26, 2024

Shanghai GenTech Co., Ltd., a Chinese solutions provider with expertise in flat panel display, LED,...

Company Deals

Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development

Fineline Cube Jul 26, 2024

Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered...

Company Deals

United Imaging Healthcare Invests RMB 120 Million in Particle Accelerator Specialist Long Beam Technology

Fineline Cube Jul 26, 2024

United Imaging Healthcare (UIH, SHA: 688271), a leading medical device company in China, has announced...

Company Drug

Sinqi Pharmaceutical Gets NMPA Green Light for SQ-22031 Eye Drops to Treat Dry Eye Syndrome and Neurotrophic Keratitis

Fineline Cube Jul 26, 2024

Shenyang Sinqi Pharmaceutical Co., Ltd (SHE: 300573), a pharmaceutical company based in China, has received...

Company Medical Device

Lepu Scientech Secures NMPA Approval for RF Lance, Advancing Atrial Septal Puncture Technology

Fineline Cube Jul 26, 2024

Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading medical technology company based...

Company Medical Device

Amoy Diagnostics’ APACE Receives Japanese Approval as Companion Diagnostic for MET-Inhibiting Therapies

Fineline Cube Jul 26, 2024

Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a Chinese diagnostics company, has announced that it...

Company Drug

China’s NMPA Gives Tacit Nod to IASO Biotechnology’s IASO-782 for SLE Clinical Trials

Fineline Cube Jul 26, 2024

IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that the National Medical Products...

Company Drug

Luye Pharma’s Subsidiary Gets NMPA Go-Ahead for First CD228-Targeted ADC BA1302

Fineline Cube Jul 26, 2024

Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a subsidiary of China-based Luye Pharma Group (HKG:...

Company

AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges

Fineline Cube Jul 26, 2024

AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024,...

Posts pagination

1 … 347 348 349 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.